The following clinical trials have been conducted under MESI-STRAT. After the embargo period of 3 years ending on October 1 2026, requests for data access can be submitted to coordinator@mesi-strat.eu which will be evaluated by the MESI-STRAT board.
| Trial number | Trial name | Trial identifier and link | Number of patients | Variables | Data types |
|---|---|---|---|---|---|
| 6.1 | Risk Detection Trial | n.a. | 243 | High risk (118 patients) versus low risk (125 patients) | Metabolomics; Serum measurements |
| 6.2 | Relapse Detection Trial | n.a. | 204 | Relapse (107 patients) versus without relapse (97 patients) | Metabolomics; Serum measurements |
| 6.3 | Relapse Prediction Trial | n.a. | 263 | Relapse/Metastasis (88 patients) versus without relapse/metastasis (175 patients); measured at diagnosis | Metabolomics; Serum measurements |
| 7.2 | Prospective Window Of Opportunity Trial (WOO2) | EudraCT number 2020-003960-22 https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-003960-22 | 56 | Before and after 3 weeks of neoadjuvant anastrozole treatment | Metabolomics; Serum measurements; Transcriptomics; Tissue measurements |
| 7.3 | Endocrine Therapy Termination (ETT) | n.a. | 203 (at diagnosis) | 1178 longitudinally collected samples at diagnosis, before end of endocrine therapy, 1 year, 2 years, 3 years and 4 years after end of endocrine therapy | Metabolomics; Serum measurements |